Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.22 USD
Change Today +0.40 / 2.24%
Volume 53.3K
As of 5:20 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

entellus medical inc (ENTL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $28.81
52 Week Low
10/2/15 - $16.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENTELLUS MEDICAL INC (ENTL)

Related News

No related news articles were found.

entellus medical inc (ENTL) Related Businessweek News

No Related Businessweek News Found

entellus medical inc (ENTL) Details

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation; and FinESS sinus dilation system, a solution for treatment of the maxillary sinus drainage pathway. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its own battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat (ENT) physicians to access the frontal sinus and trans-illuminate the sinus cavity, and forehead to confirm correct entry into the frontal sinus; Maxillary Seeker, a tool that allows users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium, and to manipulate the middle turbinate. In addition, Entellus Medical, Inc. distributes XeroGel Nasal Packing Material for use in patients undergoing nasal or sinus surgery, as well as for use as a nasal packing to treat epistaxis or nasal bleeding. The company sells its products in the United States. Entellus Medical, Inc. was founded in 2006 and is headquartered in Plymouth, Minnesota.

177 Employees
Last Reported Date: 03/19/15
Founded in 2006

entellus medical inc (ENTL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $93.0K
Executive Chairman
Total Annual Compensation: $458.9K
Vice President of Clinical, Regulatory & Qual...
Total Annual Compensation: $240.0K
Vice President of Sales
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

entellus medical inc (ENTL) Key Developments

Entellus Medical Announces Release of MiniFESS Surgical Instruments and FocESS Sinuscopes

Entellus Medical, Inc. announced the release of its MiniFESS family of products and its FocESS Sinuscopes, representing a total of eleven new products. These products are designed to enable, enhance and expand the number of patients who can benefit from the superior patient experience and improved healthcare economics offered by office-based treatment. In combination with effective local anesthesia protocols, the MiniFESS family of products features eight steel surgical instruments designed to enable procedures from turbinate reductions to anterior ethmoidectomies to be performed in the ENT physician office instead of the operating room. This transition to the ENT physician office offers patients reduced risk and requires less time than a traditional operating room procedure using general anesthesia. The FocESS Sinuscope line features three scopes with 0-, 30-, and 45-degree viewing angles. At 3 millimeters in diameter and 150 millimeters in length, and with a field of view that is as much as 30 millimeters greater than competing devices, the FocESS Sinuscopes are designed to make office procedures even easier for ENT physicians.

Entellus Medical, Inc. Announces Collaboration with Fiagon NA Corporation

Entellus Medical, Inc. announced a collaboration with Fiagon NA Corporation. The agreement enables Entellus to be the exclusive distributor of Fiagon Image Guidance Systems ("IGS") for ENT offices and ENT Ambulatory Surgery Centers in the United States. The company expects the integration of the Entellus XprESS Pro Multi-Sinus Dilation System and the Fiagon IGS to provide another level of confirmation to increase physician confidence in device placement. Entellus Medical's systems deliver proven results that are equivalent to those obtained through traditional sinus surgery, while at the same time providing an improved patient experience. The addition of the Fiagon IGS in the office setting has the potential to continue the expansion of ENT surgical procedures into the office setting through positive clinical outcomes and reduced costs to both the patient and healthcare system.

Entellus Medical, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of 2015

Entellus Medical, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenue was $15,191,000 against $12,498,000 a year ago. Loss from operations was $2,354,000 against $651,000 a year ago. Net loss was $2,868,000 or $0.15 per basic and diluted share against $1,173,000 or $0.81 per basic and diluted share a year ago. For six months, revenue was $28,693,000 against $22,673,000 a year ago. Loss from operations was $5,804,000 against $2,770,000 a year ago. Net loss was $7,216,000 or $0.46 per basic and diluted share against $3,708,000 or $2.59 per basic and diluted share a year ago. The company estimates that third quarter 2015 revenue will range from approximately $13.9 million to $14.4 million, which would represent growth of approximately 19% to 23% versus the third quarter of 2014. The company expects that gross margin for the third quarter of 2015 will range from 77.5% to 78.5% compared to 78.6% in the third quarter of 2014. Third quarter net loss is estimated to range from approximately $3.7 million to $5.3 million, or an estimated net loss of $0.20 to $0.28 per share. The estimated net loss for the third quarter includes estimated non-cash stock-based compensation of $0.7 million to $0.8 million. The company continues to expect full year 2015 revenue will be in a range of $58.5 million to $61.0 million, representing growth of 20% to 25% annually, and that gross margin will be in a range of 77% to 78% for 2015. Full year 2015 net loss is expected to be in a range of $14.0 million to $19.0 million, or a net loss of $0.80 to $1.10 per share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENTL:US $18.22 USD +0.40

ENTL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Stryker Corp $96.89 USD +0.43
View Industry Companies

Industry Analysis


Industry Average

Valuation ENTL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTELLUS MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at